Treatment of glycogen storage disease type II

Details Treatment of glycogen storage disease type II Treatment of glycogen storage disease type II

2006-06-06

2006-06-06

Meller, Michael (Department: 1655)

Chemistry: molecular biology and microbiology

Enzyme , proenzyme; compositions thereof; process for...

Reexamination Certificate

active

07056712

ABSTRACT:
Methods of treating glycogen storage disease type II, by administering acid α-glucosidase, are described, as are compositions for use in treatment of glycogen storage disease type II.

REFERENCES:
patent: 6118045 (2000-09-01), Reuser et al.
patent: WO 00/34451 (2000-06-01), None
Poenaru, L., Approach to Gene Therapy of Glycogenosis Type II (Pompe Disease),Molecular Genetics and Metabolism, 70 (3):163-169 (2000).
Hirschhorn, R., “Glycogen Storage Disease Type II: Acid α-Glucosidase (Acid Maltase) Deficiency”,The Metabolic and Molecular Bases of Inherited Disease, (77) 11:2443-2464 (1995).
Barton, N.W., et al., “Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease”,Proc. Natl. Acad. Sci, 87:1913-1916 (Mar. 1990).
Lauer, R.M., “Administration of a Mixture of Fungal Glucosidases to a Patient with Type II Glycogenosis (Pompe's Disease)”,Pediatrics, 42:672-676 (1968).
Van den Hout., et al., “Enzyme therapy for Pompe disease with recombinant human α-glucosidase from rabbit milk”,J. Inherit. Metab. Dis., 24:266-274 (2001).
Williams, J.C., et al., “Enzyme Replacement in Pompe Disease With an α-Glucosidase-Low Density Lipoprotein Complex*”,Birth Defects: Original Article Series, 16 (1):415-423 (1980).
Yang, H.W., et al., “Recombinant Human Acid α-Glucosidase Corrects Acid α-Glucosidase-Deficient Human Fibroblasts, Quail Fibroblasts, and Quail Myoblasts”,Pediatric Research, 43 (3):374-380 (1998).
Amalfitano, A., et al., “Recombinant human acid α-glucosidase enzyme therapy for infantile glycogen storage disease type II: Results of a phase I/II clinical trial”,Genetics in Medicine, 3 (2):132-138 (2001).
Ausems, M., et al., “Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling”,European Journal of Human Genetics, 7:713-716 (1999).
Bijvoet, A.G.A., et al., “Recombinant human acid α-glucosidase: high level production in mouse milk, biochemical characteristics, correction of enzyme deficiency in GSDII KO mice”,Human Molecular Genetics, 7 (11):1815-1824 (1998).
Bijvoet, A.G.A., et al., “Human acid α-glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II”,Human Molecular Genetics, 8 (12):2145-2153 (1999).
Brooks, D.A., “Immune Response to Enzyme Replacement Therapy in Lysosomal Storage Disorder Patients and Animal Models”,Molecular Genetics and Metabolism, 68:268-275 (1999).
de Barsy, T., et al., “Enzyme Replacement in Pompe Disease: An Attempt with Purified Human Acid α-Glucosidase*”,Birth Defects:Original Article Series, 9 (2):184-190 (1973).
Fuller, M., et al., “Isolation and characterisation of a recombinant, precursor form of lysosomal acid α-glucosidase”,Eur. J. Biochem, 234:903-909 (1995).
Hermans, M.M.P., et al., “The effect of a single base pair deletion (ΔT525) and a C1634T missense mutation (pro545leu) on the expression of lysosomal α-glucosidase in patients with glycogen storage disease type II”,Human Molecular Genetics, 3 (12):2213-2218 (1994).
Hermans, M.M.P., et al., “The conservative substitution Asp-645→Glu in lysosomal α-glucosidase affects transport and phosphorylation of the enzyme in an adult patient with glycogen-storage disease type II”,Biochem. J., 289:687-693 (1993).
Hermans, M.M.P., et al., “Identification of a Point Mutation in the Human Lysosomal α-Glucosidase Gene Causing Infantile Glycogenosis Type II”,Biochemical and Biophysical Research Communications, 179 (2):919-926 (1991).
Hoefsloot, L.H., et al., “Characterization of the human lysosomal α-glucosidase gene”,Biochem. J., 272:493-497 (1990).
Hug, G., et al., “Treatment Related Observations in Solid Tissues, Fibroblast Cultures and Amniotic Fluid Cells of Type II Glycogenosis, Hurler Disease and Metachromatice Leukodystrophy*”,Birth Defects: Original Articles Series, 9 (2):160-183 (1973).
Kikuchi, T., et al., “Clinical and Metabolic Correction of Pompe Disease by Enzyme Therapy in Acid Maltase-deficient Quail”,J. Clin. Invest., 101 (4):827-833 (1998).
Martiniuk, F., et al., “Recombinant Human Acid α-Glucosidase Generated in Bacteria: Antigenic, but Enzymatically Inactive”,DNA and Cell Biology, 11 (9):701-706 (1992).
Reuser, A.J.J., et al., “Biochemical, Immunological, and Cell Genetic Studies in Glycogenosis Type II”,Am J Hum Genet, 30:132-143 (1978).
Slonim, A.E., et al., “Improvement of muscle function in acid maltase deficiency by high-protein therapy”,Neurology, 33:34-38 (1983).
Van der Ploeg, A.T., et al., “Intravenous Administration of Phosphorylated Acid α-Glucosidase Leads to Uptake of Enzyme in Heart and Skeletal Muscle of Mice”,J. Clin. Invest., 87:513-518 (1991).
Wu, J-Y., et al., “Expression of Catalytically Active Human Multifunctional Glycogen-Debranching Enzyme and Lysosomal Acid Alpha-Glucosidase in Insect Cells”,Biochemistry and Molecular Biology International, 39 (4):755-764 (1996).
Watson, J.G., et al., “Bone Marrow Transplantation for Glycogen Storage Disease Type II (Pompe's Disease)”,N. Engl. J. Med., 314:385 (1986).
Martiniuk, F., et al., “Carrier Frequency for Glycogen Storage Disease Type II in New York and Estimates of Affected Individuals Born With the Disease”,American Journal of Medical Genetics, 76:69-72 (1998).
Schiffmann, R., et al., “Infusion of α-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease”,Proc. Natl. Acad. Sci., 97 (1):365-370 (2000).
Van Hove, J.L.K, et al., “High-level production of recombinant human lysosomal acid α-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease”,Proc. Natl. Acad. Sci., 93:65-70 (1996).
Lei, K.J., et al., “Genetic Basis of Glycogen Storage Disease Type 1a: Prevalent Mutations at the Glucose-6-Phosphatase Locus”, Am.J. Hum. Gen., 57 (4):766-771 (1995).
Pauly, D.F., et al., “Complete correction of acid α-glucosidase deficiency in Pompe disease fibroblasts in vitro, and lysosomally targeted expression in neonatal rat cardic and skeletal muscle”,Gene Therapy, 5 (4):473-480 (1998).
Chen, Y-T, et al., “Towards a molecular therapy for glycogen storage disease type II (Pompe disease)”,Mol. Medicine Today, 6 (6):245-251 (2000).
Kakkis, E., et al., “Recombinant α-L-iduronidase replacement therapy in mucopolysaccharidosis 1: Results of a human clinical trial”,Am. J. Hum. Genet., 63 (4):A25 (1998).
Byrne, B.J., et al., “Reconstitution of Acid α-glucosidase activity in a mouse model of cardioskeleton myopathy, Pompe's Disease”, Circulation, vol. 98 (17):I737 (1998).

Affiliated with

Also associated with

Rating

Treatment of glycogen storage disease type II does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of glycogen storage disease type II, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of glycogen storage disease type II will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3626710